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Acute respiratory infections (ARIs) are a common
reason for seeking medical attention, and the threat
of pandemic influenza will likely add to these num-
bers. Using human viral challenge studies with live
rhinovirus, respiratory syncytial virus, and influenza
A, we developed peripheral blood gene expression
signatures that distinguish individuals with symp-
tomatic ARIs from uninfected individuals with >95%
accuracy. We validated this ‘‘acute respiratory viral’’
signature—encompassing genes with a known role
in host defense against viral infections—across each
viral challenge. We also validated the signature in an
independently acquired data set for influenza A and
classified infected individuals from healthy controls
with 100% accuracy. In the same data set, we could
also distinguish viral from bacterial ARIs (93% accu-
racy). These results demonstrate that ARIs induce
changes in human peripheral blood gene expression
that can be used to diagnose a viral etiology of respi-
ratory infection and triage symptomatic individuals.
INTRODUCTION
Acute respiratory infections (ARIs) are among the most common
reasons for seeking medical attention in the United States (Hong
et al., 2004; Johnstone et al., 2008). Rhinovirus (HRV), influenza,
and respiratory syncytial virus (RSV) are recognized as leading
etiologies of ARI in adults (Peltola et al., 2008). Viral ARIs are
generally self-limited, but can lead to disease exacerbation
among individuals with prior pulmonary disease (Johnston,
1995; Rakes et al., 1999). Most adults experience at least one
HRV infection per year (Arruda et al., 1997; Schaller et al.,Cell Host2006). Adult RSV infections may be self-limited or lead to airway
obstruction and morbidity (Falsey et al., 2005). Influenza infec-
tion remains common, with associated significant healthcare
and societal costs (Gums et al., 2008). Early detection of influ-
enza A can facilitate individual treatment decisions as well as
provide early data to forecast an epidemic/pandemic (Memoli
et al., 2008).
HRV, RSV, and influenza are all spread by droplet inhalation,
and upon contact with the respiratory epithelium, these viruses
initiate a cytokine and chemokine response that orchestrates
proliferation, chemotaxis, and amplification of inflammatory cells
(Bhoj et al., 2008; Kirchberger et al., 2007). Nasal epithelial
inflammation produced on contact with virus triggers a coordi-
nated host response that may result from infection limited to
the upper respiratory tract or spread to the lower respiratory tract
with bronchiolitis and pneumonia. Understanding the host re-
sponses to these common infections will allow for better under-
standing of disease pathobiology and provide a basis for devel-
opment of novel diagnostic methodologies for distinguishing
viral respiratory infection from respiratory disease caused by
other common pathogens.
Peripheral blood leukocytes are a reservoir and migration point
for cells representing all aspects of the host immune response.
Gene expression patterns obtained from these cells can discrim-
inate between complex physiologic states (Aziz et al., 2007),
exposures to pathogens (Ramilo et al., 2007; Simmons et al.,
2007), immune modifiers (e.g., LPS) (Boldrick et al., 2002;
Kobayashi et al., 2003), and environmental exposures (Dressman
et al., 2007; Meadows et al., 2008; Wang et al., 2005). While
current infectious disease diagnostics rely on pathogen-based
detection (Chiarini et al., 2008; Lambert et al., 2008; Robinson
et al., 2008), the development of reproducible means for extract-
ing RNA from whole blood coupled with advanced statistical
methods for analysis of complex data sets now allows the possi-
bility of classifying infections based on host gene expression
profiling that reveals pathogen-specific signatures of disease.& Microbe 6, 207–217, September 17, 2009 ª2009 Elsevier Inc. 207
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a paradigm shift in the way complex, large-scale data are viewed,
analyzed, and utilized. The biology of infection, the host re-
sponse, and the ensuing disease process is highly complex.
Our previous work in defining the complexity of the cancer phe-
notype using gene expression analysis has defined approaches
involving successive subcategorization of patients according
to combinations of both clinical and genomic risk factors, high-
lighting the predictive value of multiple genomic patterns
(Acharya et al., 2008; Garman et al., 2008; Xu et al., 2008). The
role of formal statistical models to incorporate, evaluate, and
weigh multiple gene expression patterns is fundamental to this
methodology. We have shown that specific classes of statistical
tree models are capable of such synthesis and can improve
prediction and classification for individual patients. One core
methodology that underlies our comprehensive models uses
statistical prediction tree models, and the expression data enter
into these models signatures (estimated ‘‘factors’’) that are candi-
date predictive factors in statistical tree models. This approach to
molecular characterization and candidate gene identification has
provided significant value in recent work (Acharya et al., 2008;
Garman et al., 2008; Lucas et al., 2006; Meadows et al., 2008;
Seo et al., 2006), uncovering patterns of nonlinear associations
between gene expression and phenotypic outcomes (Brieman,
2001; Kooperberg et al., 2001; Ruczinski et al., 2003).
Using three human viral challenge cohorts for HRV, RSV, and
influenza A, we developed a robust blood mRNA expression
signature that classifies symptomatic human respiratory viral
infection. Factor analysis (Carvalho et al., 2008) of mRNA expres-
sion data revealed a pattern of gene expression common across
Figure 1. Diagram of Study Organization
Three unique cohorts of healthy volunteers were infected
with 1 of 3 respiratory viruses (HRV, RSV, or influenza A).
Combined data were analyzed using sparse latent factor
regression with leave-one-out cross-validation. Subse-
quent validation occurred using a data set available from
the public domain.
symptomatic individuals from all viral chal-
lenges. This was termed the ‘‘acute respiratory
viral’’ bio-signature of disease, which encom-
passed transcripts of genes known to be related
to viral infection and the overall immune re-
sponse. Further, this signature could accurately
classify influenza A infection in an independent
community-based cohort. For this signature to
serve as an important diagnostic indicator of
viral respiratory infection and for the purpose
of clinical triage and treatment decisions, it
should be distinct from the overall response to
bacterial respiratory tract infections. An analysis
of publicly available peripheral blood-based
gene expression data from patients with bacte-
rial infection indicated that the acute respiratory
viral signature was viral-infection specific and
could distinguish patients with viral and bacte-
rial infections as well as healthy controls. More-
over, bacterial and viral respiratory infections
could be accurately classified using this gene expression signa-
ture. This work emphasizes the important concept that capturing
the human host response to pathogen exposure may serve as
the basis for both diagnostic testing as well as a window into the
fundamental biology of infection.
RESULTS
Organization and data flow are shown in Figure 1. Exposures




The attack rate was 50%, as 10 of the 20 inoculated
subjects developed ARI-like symptoms and had confirmed viral
shedding (Table 1; Figures S1 and S2). Peak symptoms occurred
at 48 hr (n = 2), 72 hr (n = 4), or 96 hr (n = 4) postinoculation (median
72 hr).
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The attack rate was 45%, as 9 of the 20 inoculated subjects devel-
oped ARI-like symptoms and had confirmed viral shedding
(Table 1; Figures S1 and S2). One subject (RSV020)had late symp-
toms and uninterpretable culture data and was excluded. Peak
symptoms occurred at 93.5 hr (n = 1), 117.5 hr (n = 1), 141.5 hr
(n = 5), and 165.5 hr (n = 1) postinoculation (median 141.5 hr).
Influenza
The attack rate was 53%, as 9 of the 17 inoculated subjects
developed ARI-like symptoms and had confirmed viral shedding
(Table 1; Figures S1 and S2). Peak symptoms occurred at 50 hr
(n = 1), 62 hr (n = 2), 74 hr (n = 2), 86 hr (n = 2), 98 hr (n = 1), and
110 hr (n = 1) postinoculation (median 80 hr).
An Acute Respiratory Viral Blood Gene Expression
Signature for Classifying Symptomatic HRV, RSV,
or Influenza A Infection
Wefirstcombineddata from each challenge andanalyzed them as
a single data set. Eighty-four time points were included in the anal-
ysis (HRV: 10 baseline, 10 symptomatic, 10 matched time point
asymptomatic; RSV: 10 baseline, 9 symptomatic, 10 matched
time point asymptomatic; influenza: 8 baseline, 9 symptomatic,
8 matched time point asymptomatic). Twenty factors were devel-
oped using all available probes, and a single factor (factor 16)
could best discriminate symptomatic (infected) subjects (HRV,
RSV, or influenza A) from asymptomatic (uninfected) individuals.
Baseline (preinoculation) gene expression was indistinguishable
from the matched time point of asymptomatic subjects (Figure 2).
Baseline gene expression in subjects who became symptomatic
was indistinguishable from those who remained asymptomatic
(data not shown). The top 30 predictive genes contained in factor
16 are known to characterize host response to viral infection
(Table S1). These 30 genes were used as features for the sparse
probit regression model to perform leave-one-out cross-valida-
tion and generate an ROC curve (Figure 2) to estimate perfor-
mance of the model. Leave-one-out cross-validation correctly
identified 96.5% of infected subjects (misclassification rate
3.5%, 3 of 84). These data—from three distinct viral challenge
experiments—demonstrate a clear acute respiratory viral re-
sponse factor as a common feature of peak infection.
To further validate the robust ‘‘acute respiratory viral response’’
signature, we next analyzed each data set (HRV, RSV, and influ-
enza A) separately to identify a factor that characterized symp-
tomatic viral infection for each individual data set (Figure S3).
We performed sparse probit regression on the 30 genes with
the highest factor loading values in each factor, and these data
were used for leave-one-out cross-validation and generation of
an ROC curve to estimate factor performance. Notably, the
p-values associated with each factor (i.e., the likelihood that this
group of genes would not be selected randomly) were 2.33 3
105 (HRV), 2.29 3 107 (RSV), and 4.95 3 1013 (influenza)
(http://www.gather.duke.edu). The individual challenge-specific
factors were used as a de facto ‘‘training set’’ to classify subjects
from the other challenges. As shown in Figure S4 and Table 2,
when the model was trained on any individual data set, prediction
of symptomatic versus asymptomatic was >96%. This supports
the conclusion that, at peak viral respiratory infection symptoms,
the host response converges to encompass a gene expression
program highly characteristic of response to viral infection.Cell Host &Figure S5 shows overlap between genes represented in the
factors predictive for the individual viruses. Most genes contained
in the individual virus factors were present in the acute respiratory
viral factor. Genes unique to an individual virus factor include the
following: SOCS1 (HRV) and FCGR1A, GBP1, LAP3, ETV7, and
FCGR1B (RSV). Complete gene lists for the individual virus
factors and the acute respiratory viral factor are listed in Table
S1. Genes represented in these factors were highly representa-
tive of host response to viral infection, including RSAD2, IFN
response elements, and the OAS gene family.
Validation of the Experimental Acute Respiratory
Viral Peripheral Blood Gene Expression Signature
in an Independent Cohort with Symptomatic
Community-Acquired Influenza A
Given the strong viral response signature that distinguished
symptomatic HRV, RSV, and influenza infection from uninfected
subjects, we sought to confirm the specificity of this response to
viral infection diagnosed in a community setting. We utilized two
methods to validate our acute respiratory viral signature using
microarray data sets derived from PBMC mRNA from a published
study (Ramilo et al., 2007) of viral respiratory infection ascer-
tained a from cohort of pediatric patients with microbiologically
proven influenza A infection with linked gene expression data.
First, we used the acute respiratory viral classifier built on the
combined three challenge data sets to predict disease state
(uninfected versus influenza A infection) in the literature cohort
(Figure 3). Despite differences in subject ascertainment in the
experimental cohort and the literature cohort (as well as other
potential confounders, such as age and demographics), we
were able to accurately classify subjects as influenza A-infected
versus no infection in the literature cohort. This classification of
subjects in this cohort was highly accurate (100% [23 of 23] for
influenza-infected versus no infection) (Figure 3B). Prediction
of viral infection in a pre-existing data set using genes identified
as discriminative in an experimental data set reinforces the
robust nature of both the methodology and the classifier.
In the second approach, we reanalyzed the raw gene expres-
sion data from the literature data set (Ramilo et al., 2007) using
the same methods that were utilized to generate the HRV, RSV,
and influenza expression signatures. Similar to our analysis of
the HRV-, RSV-, and influenza-infected cohorts, 20 factors were
built using the entire gene set from all persons in the literature
cohort (Figure S6). These factors were used to build a classifier
that distinguished persons with influenza A (n = 18) from healthy
controls (n = 6 pediatric subjects hospitalized for elective
surgery). The top 30 genes in this factor were used as features
for the sparse probit regression model to perform leave-one-
out cross-validation and generate ROC curves to estimate
performance of the algorithm. Leave-one-out cross-validation
correctly identified 100% of the 24 individuals in this data set.
Of the 27 unique genes represented in the literature cohort
factor, 20 were also present in the acute respiratory viral factor
derived from the experimental cohorts. Of the 28 unique genes
represented in the acute respiratory viral factor derived from
our experimental cohorts, 20 were also present in the literature
cohort factor. The probit function was also used to discriminate
between influenza A infection and bacterial infection, with
cross-validation correctly classifying 90 of 97 subjectsMicrobe 6, 207–217, September 17, 2009 ª2009 Elsevier Inc. 209
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the acute respiratory viral factor derived above is a robust
disease signature at time of peak symptoms. Predictive perfor-
mance of each gene contained in the probit function generated
from the acute respiratory viral factor to predict pathogen class
in the independent data set is shown in Figure S7.
Peripheral Blood Gene Expression Signatures
Can Discriminate between Acute Respiratory Viral
Infection and Bacterial Infection
We next sought to further show that our acute respiratory viral
gene expression factor was specific for viral infections. We
used microarray data sets available in the literature (Ramilo
et al., 2007) derived from PBMC mRNA from a cohort of pediatric
patients with microbiologically proven S. pneumoniae (n = 13),
S. aureus (n = 31), or E. coli (n = 29) infections. We used the acute
respiratory viral classifier built on the three combined challenge
data sets to predict disease state (influenza A infection versus
bacterial infection) in the literature cohort (Figure 4). Classification
of subjects in the literature cohort was highly accurate: 80% (73 of
91) for influenza-infected versus any bacterial infection (Figure 4)
and 93% (31 of 33) for influenza-infected versus pneumococcal
infection. This analysis confirms specificity of the viral infection
signature to discriminate not only between subjects with acute
respiratory viral infection and uninfected subjects, but also from
subjects with acute bacterial infections, including bacterial
respiratory infection. Ultimately, the differentiation that is most
valuable clinically may be discriminative between host response
to viral respiratory tract infection and bacterial pneumonia
Table 2. Intra-Data Set Probit Classification Cross-Validation
Results
Test: HRV Test: RSV Test: Influenza
Train: HRV 1/30 (RSAD2) 2/29 (RTP4) 0/25 (ISG15)
Train: RSV 1/30 (RSAD2) 2/29 (RTP4) 0/25 (ISG15)
Train: Influenza 1/30 (RSAD2) 2/29 (RTP4) 0/25 (ISG15)
The error rate is shown based on the top gene (noted in parentheses)
selected from the training set probit classifier. For this model, the top
40 genes from the training set discriminative factor were used to build
the probit classifier for testing in the validation data set.Cell Host &(i.e.,S. pneumoniae infection). Thus, despite inherent differences
in sample acquisition and study design between the experimental
HRV, RSV, and influenza cohorts and the literature cohort, these
analyses confirm the robust nature of gene expression signatures
that differentiate subjects with respiratory viral infection from
subjects with bacterial infections, including pneumococcal infec-
tion, and from healthy subjects.
DISCUSSION
We performed three independent human viral challenge studies
(HRV, RSV, and influenza) to define host-based peripheral blood
gene expression patterns characteristic of response to viral
respiratory infection. The results provide clear evidence that
a unique biologically relevant peripheral blood gene expression
signature classifies respiratory viral infection with a remarkable
degree of accuracy. These findings underscore the conserved
nature of the host response to viral infection, which is also
evident in the cross-validation between experimental cohorts.
The ‘‘acute respiratory viral’’ gene expression signature derived
from these cohorts was validated in an independently derived
external data set and, importantly, can distinguish respiratory
viral infection from bacterial infection. These findings provide
compelling evidence that peripheral blood gene expression
can function as a biomarker for specific classes of infectious
pathogens and may potentially serve as a useful diagnostic for
triaging treatment decisions for ARI.
Discrimination between infectious causes of illness is a critical
component of acute care of the medical patient, as such distinc-
tions facilitate both triage and treatment decisions. While tradi-
tional culture, antigen-based, and PCR-based diagnostics are
useful in pathogen classification, these assays are not without
limitations (Bryant et al., 2004; Campbell and Ghazal, 2004).
Current rapid diagnostic methods are lacking in sensitivity,
with influenza and RSV tests (e.g., BinaxNOW antigen testing) re-
porting sensitivities of 53%–80% (Jonathan, 2006; Landry et al.,
2008; Rahman et al., 2008), or are labor intensive, such as direct-
fluorescent antibody (DFA) testing. Categorizing infection based
on host response is an emerging hypothesis that not only
enhances our diagnostic capabilities, but may provide additional
insight into the pathobiology of infection. We have identifiedFigure 2. An Acute Respiratory Viral Gene Expression Signature Characterizes Symptomatic Respiratory Viral Infection
(A) Heat map representing gene expression for genes contained in factor 16. Experimentally infected adult subjects with symptomatic HRV, RSV, or influenza A
infection can be distinguished from uninfected individuals by a distinct group of genes (‘‘factor’’) demonstrating differential expression among symptomatic indi-
viduals as compared to asymptomatic individuals. For each viral challenge, peripheral blood was drawn for whole-blood gene expression analysis at scheduled
time points after intranasal inoculation of virus. Whole-blood gene expression was determined preinoculation (baseline) and at the time of peak symptoms (T) for
each symptomatic individual and at a matched time point for each asymptomatic individual. For (A), columns represent subjects and correspond to points in (B),
with the first ten columns representing baseline gene expression of asymptomatic individuals in the HRV challenge, the next ten columns representing time points
matched to peak symptoms for the asymptomatic subjects in the HRV cohort, and the following ten columns representing time of peak symptoms for the ten
subjects who developed symptomatic HRV infection. A similar layout continues for the RSV and influenza cohorts. Blue and red represent extremes of gene
expression, with visually apparent differences between baseline and matched time points in the asymptomatic individuals versus time of peak symptoms in
symptomatic individuals. The initial models were built without label information for each subject (asymptomatic versus symptomatic, baseline time point versus
infected/matched time point). This design allowed the model to cluster individuals based on expression patterns alone, thus minimizing bias in factor organiza-
tion. Bars underneath represent individual groups (black, baseline; red, asymptomatic; blue, symptomatic). P value (ANOVA) for the difference in factor scores
between symptomatic and asymptomatic subjects at time T for the combined data set is <13 1016; for HRV, 2.53 105; for RSV, 2.33 107; and for influenza,
5.0 3 1013).
(B) Factor plots representing categorization of asymptomatic and symptomatic subjects at baseline (black), matched time point to peak symptoms (asymptom-
atic, red), and peak symptoms (symptomatic, blue).
(C) Leave-one-out cross-validation correctly identifies 97% of individuals with viral infection versus no infection (3 of 84 misclassified). Pd, probability of
detection; Pf, probability of false discovery.Microbe 6, 207–217, September 17, 2009 ª2009 Elsevier Inc. 211
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infection and that identify infected individuals with a high degree
of accuracy. Several lines of evidence validate our findings, in-
cluding the internal cross-validation between exposure cohorts,
as well as validation with the free-living influenza A and bacterial
infection pediatric cohort (Ramilo et al., 2007). Other investiga-
tors have identified host gene expression patterns—in nasal
epithelium—that are associated with viral infection. Differentially
expressed genes in nasal epithelium exposed to HRV-16 (in vitro
and from experimentally infected subjects) were similar to those
found in the current study in peripheral blood (Proud et al., 2008).
In particular, RSAD2 (viperin), a potential antiviral molecule (Chin
and Cresswell, 2001; Jiang et al., 2008; Wang et al., 2007b), was
the most highly differentially expressed gene in nasal epithelium
between infected and uninfected individuals at 48 hr after inoc-
ulation. Our HRV (HRV-16) predictive factor included RSAD2
(viperin), and the probit regression model selected it as the key
differentially expressed gene in blood for determining infected
state in the HRV cohort. Whole-blood gene expression studies
Figure 3. Acute Respiratory Viral Factor Derived
from the Three Experimental Cohorts (HRV, RSV,
and Influenza) Predicts Subjects with Culture-
Proven Influenza Infection from an Independent
Data Set with a High Degree of Accuracy
(A) Predictive capability of the acute respiratory viral factor
to classify subjects with no infection (red) versus influenza
A infection (blue). The acute respiratory viral classifier built
on the combined three challenge data sets was used to
predict disease state (uninfected versus influenza A infec-
tion) in the literature cohort. x axis represents the individual
subjects, and y axis represents the decision threshold.
The threshold for generation of the subsequent ROC
curves is chosen as 0.5.
(B) Prediction of influenza A-infected versus healthy hospi-
talized control subjects using the acute respiratory viral
classifier. Classification of subjects in the literature cohort
was highly accurate (100% [23 of 23] for influenza-infected
versus no infection).
looking at RSV infection in hospitalized infants
shared differentially expressed genes with the
RSV factor found in our study, with a predomi-
nance of IFN-response elements FCg1AR and
OAS3 (Fjaerli et al., 2006). Finally, data from
the naturally occurring influenza A/bacterial
infection study (Ramilo et al., 2007) confirmed
a distinct host response signature to viral infec-
tion occurring both in this cohort and our exper-
imentally infected cohorts. Taken together, this
provides strong evidence for highly accurate
in vivo detection of human viral respiratory
infection through analysis of peripheral blood
gene expression. Notably, different peripheral
blood immune cell types induce varying gene
expression programs in response to pathogen
exposure. Thus, the peripheral blood gene
expression signatures derived and validated in
these cohorts may be applicable only to individ-
uals without underlying immune deficiencies.
Additional studies in immune-deficient populations will be
needed to generalize the current findings to these rare but clini-
cally important patient subsets.
Evident from the genes in each factor, signatures that discrim-
inate subjects with symptomatic respiratory viral infections from
healthy subjects and subjects with bacterial infection contain bio-
logically plausible gene networks involved in host viral response.
The acute respiratory viral factor was most heavily represented
by genes in the IFN-signaling canonical pathway (p = 9.75 3
109) and the pattern-recognition pathway for bacteria and
viruses (p = 5.67 3 105). This overrepresentation of IFN
response elements remained when individual viral challenges
were analyzed as separate entities (HRV, p = 1.38 3 1010;
RSV, p = 2.25 3 109; influenza, p = 1.25 3 107) (http://www.
ingenuity.com). Overlap between the genes defining each factor
(discriminating symptomatic individuals versus asymptomatic
individuals or discriminating viral respiratory infection from
bacterial infection) was strong. Baseline gene expression among
all challenge subjects was similar and indistinguishable from the212 Cell Host & Microbe 6, 207–217, September 17, 2009 ª2009 Elsevier Inc.
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subjects from one cohort based on the other cohorts was remark-
ably accurate. Discovery of discriminant factors for disease
states such as this one is inherently blind to biology, as the model
is not aware of data labels. Despite differences in study design,
commonalities between experimentally infected adults with
HRV, RSV, or influenza A and community-infected children with
influenza A predominated over virus-specific aspects of each
signature. However, when selecting the gene or genes with great-
est discriminating power for leave-one-out cross-validation, the
model chose different genes for each viral illness (HRV: RSAD2;
RSV: RTP4; influenza A: ISG15; viral versus bacterial: IFI27,
RSAD2, IFI6,CXCL10, FLJ20035,GBP1, and SIGLEC1; and viral
versus S. pneumoniae: RSAD2). Thus, with careful exploration of
disease biology or with additional cohorts for validation, disease-
specific markers of infection may arise, adding parity to the diag-
nostic signatures. Overlap is minimal with differentially expressed
genes from other studies of peripheral blood response to environ-
mental stress found in a study of humans exposed to ionizing
radiation and the genotoxic stress of chemotherapy and LPS
Figure 4. Classification of Viral and Bacterial In-
fection Using the Acute Respiratory Viral Signature
(A and B) Acute respiratory viral factor derived from the
three experimental cohorts (HRV, RSV, and influenza)
distinguishes subjects from an independent data set
with culture-proven influenza infection versus bacterial
infection (blue, influenza A; green, S. pneumoniae; yellow,
S. aureus; turquoise, E. coli) with a high degree of accu-
racy. Prediction of bacterial infection (any) versus influ-
enza A infection using the pan-respiratory viral classifier
is shown in (B). Classification is accurate (80%, 73 of 91)
for influenza A infection versus any bacterial infection.
(Dressman et al., 2007; Meadows et al., 2008),
decreasing the likelihood that these genes are
part of a generalized response program inherent
to immune effector cells.
Despite data acquisition and processing
differences, gene expression patterns derived
from publicly available microarray data for indi-
viduals with influenza A infection were similar to
those with experimentally acquired symptom-
atic HRV, RSV, or influenza A infection. Genes
found to characterize the response to respira-
tory viral infection in our cohorts overlap with
genes found in many gene expression studies
of host response to viral infections, both
in vivo (Bhoj et al., 2008; Proud et al., 2008;
Ramilo et al., 2007) and in vitro (Jenner and
Young, 2005). This generalizability of the respi-
ratory viral response signature finding illustrates
that the host response to respiratory viral infec-
tions is robust and conserved such that it can be
discerned in divergent patient populations
(healthy adult volunteers experimentally in-
fected with HRV or RSV and children hospital-
ized with influenza A). Second, this finding illus-
trates the dominance of a pathogen-specific
response at time of peak symptoms over a generalized ‘‘infec-
tion’’ response, as discrimination between viral and bacterial
infection is possible. The ability of these signatures to differen-
tiate between pathogen classes (viral versus bacterial) provides
a marked distinction between these findings and current
methods of infectious or inflammatory illness classification
(e.g., peripheral white blood cell count or measurement of
inflammatory markers such as C-reactive protein). The sensitivity
and specificity of these markers both in our experimental setting
and when applied to a cohort from the literature data represent
an improvement on the performance of current rapid (e.g., rapid
antigen testing) diagnostics as well as current culture-based
diagnostics. A combination of these tests may ultimately prove
to offer the best sensitivity and specificity for disease diagnosis.
These data provide an important backbone to the concept that
host peripheral blood gene expression may be a valuable tool
alone or in conjunction with standard microbiologic testing for
infectious diseases. Validation in an additional community-
based cohort, as well as developing signatures to diagnose
presymptomatic viral respiratory infections, is desirable.Cell Host & Microbe 6, 207–217, September 17, 2009 ª2009 Elsevier Inc. 213
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Factor Occurs Earlier than Time of Peak Symp-
toms
Factor trajectory for the acute respiratory viral factor
described in Figure 2 is shown for the symptomatic
(blue) and asymptomatic (red) subjects from the influenza
challenge study. Notably, factor 16 is detectable prior to
the timing of peak symptoms. Each point represents the
average factor score for the samples that fall into that
group, with error bars representing the SD. For example,
the blue dot at time 0 represents all samples from subjects
immediately postinoculation who will subsequently
become symptomatic (nine subjects). A t test was per-
formed at teach time point for difference in factor score
from those who will become symptomatic and from those
who will remain asymptomatic. The difference between
factor scores for symptomatic and asymptomatic became
significant at p < 0.03 at 45.5 hr and continued through the
end of the measurements. *p < 0.03.An important question that arises is whether the changes in host
gene expression described here occur before peak symptoms.
While still preliminary, we have time course data on subsets of
these cohorts. The factor analysis was applied using the RSV,
HRV, and influenza data from all samples at all times, from which
the factor discussed above (factor 16)wasconstituted. In Figure 5,
we plot the factor score (strength) of the discriminative factor as
a function of time. Two curves are depicted, representing the
average factor scores, averaged separately for those that would
eventually be symptomatic and those that would not. The differ-
ences in f scores between individuals who remain asymptomatic
and those who become symptomatic reachstatistical significance
(p = 0.028) at 45.5 hr following inoculation. This factor was found to
be detectable prior to development of peak symptoms among
symptomatic individuals. Thus, using host response as the diag-
nostic paradigm, presymptomatic diagnosis may be possible.
Signature validation across experimentally infected cohorts
illustrates the robust nature of the host response to viral infec-
tion. Additional validation of the gene expression signatures in
other community-based cohorts would elevate these findings
to a true diagnostic test that could enhance or supersede tradi-
tional microbiologic-based diagnostics. Additionally, such data
would be extremely valuable if they could be used to either diag-
nose infection class prior to standard microbiologic studies (i.e.,
in the early phases of disease) or indicate prognosis following
disease acquisition or therapeutic intervention. In our study,
we were able to utilize an easily obtained sample (peripheral
blood) to characterize response to a respiratory infection. While
development of a diagnostic test that utilizes host gene expres-
sion to characterize or predict infectious diseases is not yet
possible from the data generated in this study, it represents an
important advance showing that peripheral blood gene expres-
sion can be used to characterize host response to infection.
EXPERIMENTAL PROCEDURES
All exposures were approved by the relevant institutional review boards and
conducted according to the Declaration of Helsinki. Funding for this study214 Cell Host & Microbe 6, 207–217, September 17, 2009 ª2009 Elswas provided by the US Defense Advanced Research Projects Agency
(DARPA) through contract N66001-07-C-2024.
Human Viral Challenges
HRV Cohort
We recruited healthy volunteers (n = 20) via advertisement to participate in the
HRV challenge study through an active screening protocol at the University of
Virginia (Charlottesville, VA). Subjects who met inclusion criteria underwent
informed consent and prescreening for serotype-specific anti-HRV approxi-
mately 2 weeks prior to the study start date. On the day prior to inoculation,
subjects underwent repeat HRV antibody testing as well as baseline laboratory
studies, including complete blood count, serum chemistries, and hepatic
enzymes. On the day of inoculation, 106 TCID50 GMP HRV serotype 39
(Charles River Laboratories; Malvern, PA) was inoculated intranasally accord-
ing to published methods (Drake et al., 2000; Gwaltney et al., 1992; Turner,
2001). Subjects were admitted to the quarantine facility for 48 hr following
HRV inoculation and remained for 48 hr following inoculation. Blood was
sampled into RNA PAXgene collection tubes (PreAnalytiX; Franklin Lakes,
NJ) at predetermined intervals postinoculation. Nasopharyngeal (NP) lavage
samples were obtained from each subject daily for HRV titers to accurately
gauge the success and timing of the HRV inoculation. Following the 48th
hour after inoculation, subjects were released from quarantine and returned
for 3 consecutive mornings for sample acquisition and symptom score ascer-
tainment.
RSV Cohort
A healthy volunteer intranasal challenge with RSV A was performed in a manner
similar to the HRV challenge. The RSV challenge was performed by Retro-
screen Virology, Ltd. (London) in 20 prescreened volunteers (n = 20) who
provided informed consent. On the day of inoculation, a dose of 104 TCID50
RSV (serotype A) manufactured and processed under current good
manufacturing practices (cGMP) by Meridian Life Sciences, Inc. (Memphis,
TN) was inoculated intranasally per standard methods. Blood and NP lavage
collection methods were similar to the HRV cohort, but continued throughout
the quarantine. Due to the incubation period of RSV A, subjects were not
released from quarantine until after the 288th hour and were negative by rapid
RSV antigen detection (BinaxNOW Rapid RSV Antigen; Inverness Medical
Innovations, Inc.; Stockport, UK).
Influenza Cohort
A healthy volunteer intranasal challenge with influenza A/Wisconsin/67/2005
(H3N2) was performed at Retroscreen Virology, Ltd. (Brentwood, UK) in 17
prescreened volunteers (n = 17) who provided informed consent. On the day
of inoculation, a dose of 106 TCID50 influenza A manufactured and processed
under cGMP by Baxter BioScience (Vienna) was diluted and inoculatedevier Inc.
Cell Host & Microbe
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1:10000) with four or five subjects receiving each dose. Due to the incubation
period, subjects were not released from quarantine until after the 168th hour.
Blood and NP lavage collection continued throughout the duration of the quar-
antine. All subjects received oral oseltamivir (Roche Pharmaceuticals) (75 mg)
by mouth twice daily at day 6 following inoculation and were negative by rapid
antigen detection (BinaxNOW Rapid Influenza Antigen; Inverness Medical
Innovations, Inc.) at time of discharge.
Case Definitions
Symptoms were recorded twice daily using standardized symptom scoring
(Jackson et al., 1958). The modified Jackson score requires subjects to rank
symptoms of upper respiratory infection (stuffy nose, scratchy throat, head-
ache, cough, etc.) on a scale of 0–3 of ‘‘no symptoms,’’ ‘‘just noticeable,’’
‘‘bothersome but can still do activities,’’ and ‘‘bothersome and cannot do daily
activities.’’ Modified Jackson scores were tabulated to determine if subjects
became symptomatic from the respiratory viral challenge. A modified Jackson
score ofR 6 over the quarantine period was the primary indicator of success-
ful viral infection (Turner, 2001), and subjects with this score were denoted as
’’symptomatic, infected.’’ Viral titers from daily NP washes were used as
corroborative evidence of successful infection using quantitative culture (Bar-
rett et al., 2006; Jackson et al., 1958; Turner, 2001).
Subjects were classified as ‘‘asymptomatic, not infected’’ if the Jackson
score was less than 6 over the 5 days of observation, and viral shedding
was not documented after the first 24 hr subsequent to inoculation. Standard-
ized symptom scores were tabulated at the end of each study to determine
attack rate and time of maximal symptoms (time ‘‘T’’).
Sample Collections
Subjects had peripheral blood in PAXgene tubes taken 24 hr prior to inocula-
tion with virus (baseline), immediately prior to inoculation (prechallenge), and at
set intervals following challenge. For the HRV challenge, peripheral blood was
taken at baseline, then at 4 hr intervals for the first 24 hr, then 6 hr intervals for
the next 24 hr, then 8 hr intervals for the next 24 hr, and then 24 hr intervals for
the remaining 3 days of the study. For the RSV and influenza challenges,
peripheral blood was taken at baseline, then at 8 hr intervals for the initial
120 hr, and then 24 hr for 2 further days. Samples were aliquoted and frozen
at 80C immediately. This study is focused on comparison of baseline
samples with RNA PAXgene samples taken at time of peak symptoms. PAX-
gene RNA from the time point of maximal symptoms was chosen for hybridiza-
tion to Affymetrix U133A human microarrays for further analysis. For all results
reported, gene expression signatures were evaluated at the time of maximal
symptoms following viral inoculation for symptomatic subjects and a matched
time point for asymptomatic subjects. Baseline (preinoculation) samples were
also analyzed.
Community Influenza and Bacterial Infection (‘‘Literature’’) Cohort
Raw data from Ramilo et al. (Ramilo et al., 2007) were obtained from the public
domain database GEO and were analyzed independently using methods
described below.
RNA Purification/Microarray Analysis
RNA was extracted at Expression Analysis (Durham, NC) from whole blood
using the PAXgene 96 Blood RNA Kit (PreAnalytiX; Valencia, CA) employing
the manufacturer’s recommended protocol. Complete methodology can
be viewed in the Supplemental Experimental Procedures. Hybridization and
microarray data collection were performed at Expression Analysis using the
GeneChip Human Genome U133A 2.0 Array (Affymetrix; Santa Clara, CA).
Statistical Analysis
Using just the data from the influenza challenge, we tested (Kruskal-Wallis)
each probe for differential expression between subjects who were sick versus
healthy at Time T. Due to the small sample size, there were no probes showing
significant association after correction for multiple hypotheses (Bonferroni).
We then analyzed jointly the results from all three trials in an ANOVA frame-
work. In addition to the intercept term, we included in the design matrix indica-
tors of sick versus healthy, t0 versus tmax, indicators for each of HRV and RSV,
and interaction terms for HRV-sick and RSV-sick (Supplemental Data).
Following robust multichip average (RMA) normalization of raw probe data,
sparse latent factor regression analysis was applied to each data set (Carvalho
et al., 2008; Lucas et al., 2006; Wang et al., 2007a). This reduces the dimen-
sionality of the complex gene expression array data set, assuming thatCell Hostmany of the probe sets on the expression array chip are highly interrelated (tar-
geting the same genes or genes in the same pathways). Dimension reduction is
performed by constructing factors (groups of genes with related expression
values). These are used in a sparse linear regression framework to explain
the variation seen in all of the probe sets. By default, most of the coefficients
in this linear regression are zero. Thus, a small number (e.g., 20) of factors
explain variation seen in any single data set. Factor loadings are defined as
the coefficients of the factor regression, and to explore the biological relevance
of any particular factor, we examine the genes that are ‘‘in’’ that factor: the
genes that show significantly nonzero factor loadings. ‘‘Factor scores’’ are
defined as the vector that best describes the coexpression of the genes in
a particular factor. Both factor loadings and factor scores are fit to the data
concurrently. While 20 factors were used for the results reported here, we
also considered 30 and 40, with minimal effect on the significant factor load-
ings. The initial models were derived using an unsupervised process (Acharya
et al., 2008) (i.e., the model classified subjects based on gene expression
pattern alone, without a priori knowledge of infection status). The top 30 genes
in each factor were used as features for the sparse probit regression model to
perform leave-one-out cross-validation and generate ROC curves to estimate
performance of the algorithm. The probit regression model selects the ‘‘top’’
predictive gene from the gene set for sample classification and generation of
an ROC curve. Validation of the factor most discriminative between the
asymptomatic and symptomatic state was performed using labeled data. Vali-
dation between data sets (HRV, RSV, and influenza A) was performed by
training the regression model on one set of data (i.e., one viral exposure)
and using this model to predict health or disease in a different data set (i.e.,
a different viral exposure). Validation of the model using the publicly available
data set was performed by utilizing the joint factor analysis on the viral expo-
sure data set (HRV, RSV, and influenza), building a probit classifier using the
top 30 genes from the most predictive factor, and applying this classifier to
the publicly available data set to estimate the predictive performance of the
acute respiratory viral classifier.
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